Suppr超能文献

基于证据的实践在医院环境中管理毛细支气管炎婴儿中的可持续性 - PREDICT 研究方案。

Sustainability of evidence-based practices in the management of infants with bronchiolitis in hospital settings - a PREDICT study protocol.

机构信息

Australian Catholic University, 40 Edward Street, North Sydney, NSW, 2060, Australia.

Emergency Research, Murdoch Children's Research Institute, The Royal Children's Hospital, Level 4 West, 50 Flemington Road, Parkville, VIC, 3052, Australia.

出版信息

BMC Health Serv Res. 2022 Aug 29;22(1):1099. doi: 10.1186/s12913-022-08450-z.

Abstract

BACKGROUND

Understanding how and why de-implementation of low-value practices is sustained remains unclear. The Paediatric Research in Emergency Departments International CollaboraTive (PREDICT) Bronchiolitis Knowledge Translation (KT) Study was a cluster randomised controlled trial conducted in 26 Australian and New Zealand hospitals (May-November 2017). Results showed targeted, theory-informed interventions (clinical leads, stakeholder meetings, train-the-trainer workshop, targeted educational package, audit/feedback) were effective at reducing use of five low-value practices for bronchiolitis (salbutamol, glucocorticoids, antibiotics, adrenaline and chest x-ray) by 14.1% in acute care settings. The primary aim of this study is to determine the sustainability (continued receipt of benefits) of these outcomes at intervention hospitals two-years after the removal of study supports. Secondary aims are to determine sustainability at one-year after removal of study support at intervention hospitals; improvements one-and-two years at control hospitals; and explore factors that influence sustainability at intervention hospitals and contribute to improvements at control hospitals.

METHODS

A mixed-methods study design. The quantitative component is a retrospective medical record audit of bronchiolitis management within 24 hours of emergency department (ED) presentations at 26 Australian (n = 20) and New Zealand (n = 6) hospitals, which participated in the PREDICT Bronchiolitis KT Study. Data for a total of 1800 infants from intervention and control sites (up to 150 per site) will be collected to determine if improvements (i.e., no use of all five low-value practices) were sustained two- years (2019) post-trial (primary outcome; composite score); and a further 1800 infants from intervention and control sites will be collected to determine sustained improvements one- year (2018) post-trial (secondary outcome). An a priori definition of sustainability will be used. The qualitative component will consist of semi-structured interviews with three to five key emergency department and paediatric inpatient medical and nursing staff per site (total n = 78-130). Factors that may have contributed to sustaining outcomes and/or interventions will be explored and mapped to an established sustainability framework.

DISCUSSION

This study will improve our understanding of the sustainability of evidence-based bronchiolitis management in infants. Results will also advance implementation science research by informing future de-implementation strategies to reduce low-value practices and sustain practice change in paediatric acute care.

TRIAL REGISTRATION

Australian and New Zealand Clinical Trials Registry No: ACTRN12621001287820.

摘要

背景

了解如何以及为何持续停止实施低价值实践仍然不清楚。儿科急诊国际合作研究(PREDICT)毛细支气管炎知识转化(KT)研究是一项在 26 家澳大利亚和新西兰医院进行的集群随机对照试验(2017 年 5 月至 11 月)。结果表明,有针对性的、基于理论的干预措施(临床负责人、利益相关者会议、培训师培训研讨会、有针对性的教育包、审计/反馈)可有效减少在急性护理环境中使用五种低价值毛细支气管炎实践(沙丁胺醇、糖皮质激素、抗生素、肾上腺素和胸部 X 光)14.1%。本研究的主要目的是确定在研究支持去除两年后,干预医院这些结果的可持续性(持续受益)。次要目标是确定干预医院在研究支持去除一年后的可持续性;控制医院一至两年的改善情况;并探讨影响干预医院可持续性并有助于改善控制医院的因素。

方法

采用混合方法研究设计。定量部分是对 26 家澳大利亚(n=20)和新西兰(n=6)医院急诊部门(ED)就诊后 24 小时内毛细支气管炎管理的回顾性病历审计,这些医院参与了 PREDICT 毛细支气管炎 KT 研究。将收集总共 1800 名来自干预和对照点(每个点最多 150 名)的婴儿的数据,以确定在试验后两年(2019 年)(主要结果;综合评分)是否持续改善(即,五种低价值实践均未使用);还将从干预和对照点收集另外 1800 名婴儿的数据,以确定在试验后一年(2018 年)持续改善(次要结果)。将使用预先定义的可持续性定义。定性部分将包括每个地点(共 78-130 名)三名至五名关键急诊和儿科住院医疗和护理人员的半结构化访谈。将探讨可能有助于维持结果和/或干预措施的因素,并将其映射到既定的可持续性框架。

讨论

本研究将提高我们对婴儿基于证据的毛细支气管炎管理可持续性的理解。结果还将通过为减少低价值实践和维持儿科急性护理实践变革提供未来的去实施策略来推进实施科学研究。

试验注册

澳大利亚和新西兰临床试验注册中心号:ACTRN12621001287820。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45b3/9426022/c107ed33cb29/12913_2022_8450_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验